REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/07/2025
Back to search
Official data from USPTO
EPCARG
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
EPCARG
ST13
US500000088278778Class
1, 5, 40, 42
Filing
88278778
Registration
6026619
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
51
Latest update
04/08/2025
Trademark type
Word
Nice classes
1, 5, 40, 42
Filing date
01/28/2019
Registration date
04/07/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/07/2020
Last transaction
04/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Bonn, DE
Examiner
MIZELLE HOWARD, DEZMONA
Law office
M10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NEUWAY Pharma GmbH
Representatives
LEIGH ANN LINDQUIST SUGHRUE MION, PLLC
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiologicalbiochemical and biotechnological products and preparations for industrial and scientific purposessmall moleculesbiologicsnucleic acidsproteinslipidspolysaccharidesenzymesantibodiescellsmicroorganismsprotein-based capsids or particles as well as fragmentsfractions and derivatives thereof
Class 5
Diagnostic preparations for medical purposes; vaccines; pharmaceutical preparationsadjuvantscarriers for active ingredients and drug delivery systems based on an engineered protein capsule for medical use in humans or animalsimplants comprising active ingredients for the prevention or treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunction and pain as well as for gene therapyvaccination or immunostimmulation; all the aforementioned goods only being either drug delivery agents based on an engineered protein capsule or pharmaceutical products or preparations for use with a drug delivery agent or system based on an engineered protein capsule; none of the aforementioned goods for use in connection with the treatment or prevention of hepatitis
Class 40
Manufacture of pharmaceutical productsmedicinal productsmedicaments from pharmaceutical compositions for third parties; all the aforementioned only in relation to drug delivery agents or systems based on an engineered protein capsule and/or pharmaceutical products or preparations for use with a drug delivery agent or system based on an engineered protein capsule; none of the aforementioned for use in connection with the treatment or prevention of hepatitis
Class 42
Scientific research and development for third partiesin particular in the fields of medicinepharmacydiagnosticschemistrybiologybiochemistry and biotechnology; scientific research and development with regard to the manufacture of pharmaceutical preparationscarriers for active ingredients and drug delivery systems for use in humans or animalsfor third parties; development of pharmaceutical preparationsmedical products for the prevention and treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunction and pain as well as for gene therapyvaccination or immunostimmulationfor third parties
Publications
History of USPTO decisions and trademark events.
51 publications found
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/26/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/26/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/26/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/26/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/26/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
04/07/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/21/2020
PUBO
PUBLISHED FOR OPPOSITION
01/21/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/01/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/17/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
12/17/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/16/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
12/16/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/16/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/22/2019
GNRT
NON-FINAL ACTION E-MAILED
11/22/2019
CNRT
NON-FINAL ACTION WRITTEN
11/22/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
11/01/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/01/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
11/01/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/01/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/15/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/15/2019
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/15/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
10/09/2019
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
10/09/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
07/17/2019
GNSL
LETTER OF SUSPENSION E-MAILED
07/17/2019
CNSL
SUSPENSION LETTER WRITTEN
07/17/2019
DMCC
DATA MODIFICATION COMPLETED
06/27/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/27/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/12/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/10/2019
GNSL
LETTER OF SUSPENSION E-MAILED
06/10/2019
CNSL
SUSPENSION LETTER WRITTEN
06/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/21/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/21/2019
ALIE
ASSIGNED TO LIE
05/17/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/10/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/09/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/12/2019
GNRT
NON-FINAL ACTION E-MAILED
04/12/2019
CNRT
NON-FINAL ACTION WRITTEN
04/12/2019
DOCK
ASSIGNED TO EXAMINER
04/09/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
02/25/2019
ALIE
ASSIGNED TO LIE
02/21/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/20/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
02/14/2019
NWAP
NEW APPLICATION ENTERED
01/31/2019
Continuous trademark protection
Get notified about every new filing that threatens EPCARG or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.